Imatinib - Exvastat

Drug Profile

Imatinib - Exvastat

Alternative Names: Imatinib Mesylate - Exvastat

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exvastat
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lung injury

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Acute lung injury in United Kingdom (PO) before November 2017 (Exvastat website, November 2017)
  • 03 Nov 2017 Exvastat and Parexel plans a phase I trial for Acute lung injury (In volunteers) in United Kingdom in November 2017 (NCT03328117) (EudraCT2017-002203-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top